All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 913-919

  Tawfik, Hesham ^a   Rostom, Yousri ^b   Elghazaly, Hesham ^c  

^a TANTA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

First line chemotherapy; HER2 Neu negative; Metastatic breast cancer; Oral therapy

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; VINBLASTINE;

ADULT; AGED; ALOPECIA; ARTICLE; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; BREAST TUMOR; CHEMISTRY; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; VINBLASTINE;

MLCS; MLOWN;

EID: 84878843440     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2082-4     Document Type: Article

References (33)

1. DeSantis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics, 2011. CA Cancer J Clin 61(6):409-418. doi: 10.3322/caac.20134
2. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34(2):405-412. doi: 10.1093/ije/dyh414 (Pubitemid 40645331)
3. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137-2150. doi: 10.1200/JCO.2005.05.2308 (Pubitemid 46655601)
4. Finek J, Holubec L Jr, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, Sediva M, Filip S, Kozevnikova R, Kormunda S (2009) A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 29(2):667-670
5. De Mattos-Arruda L, Cortes J (2012) Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist. doi: 10.1634/theoncologist.2011-0187
6. Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7(1):22-36. doi: 10.1038/nrclinonc.2009.186
7. Henderson IC (2011) Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park) 25(2):115-124, 127
8. Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65(4):755-763. doi: 10.1007/s00280-009-1081-y
9. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92-98. doi: 10.1200/JCO.2008.19.9844
10. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V (1989) In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16(2 Suppl 4):5-8 (Pubitemid 19137820)
11. Saif MW, Katirtzoglou NA, Syrigos KN (2008) Capecitabine: an overview of the side effects and their management. Anticancer Drugs 19(5):447-464. doi: 10.1097/CAD.0b013e3282f945aa (Pubitemid 351556397)
12. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A (2009) Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64(4):673-680. doi: 10.1007/s00280-008-0915-3
13. Sawada N, Fujimoto-Ouchi F, Ishikawa T (2002) Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models [abstract 5388]. Proc Am Assoc Cancer Res 43:1088a
14. Chan A, Verrill M (2009) Capecitabine and vinorelbine in metastatic breast cancer. Eur J Cancer 45(13):2253-2265. doi: 10.1016/j.ejca.2009.04.031
15. Cardoso F, Castiglione M (2009) Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):15-18. doi: 10.1093/annonc/mdp115
16. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E (2011) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi25-vi30. doi: 10.1093/annonc/mdr372
17. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110-115 (Pubitemid 27021524)
18. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12(11):1643-1649 (Pubitemid 34070598)
19. Aapro M, Finek J (2012) Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev 38(2):120-126. doi: 10.1016/j.ctrv.2011.05.005
20. Estevez LG, Batista N, Sanchez-Rovira P, Velasco A, Provencio M, Leon A, Domine M, Cruz J, Rodriguez M (2008) A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 8(2):149-154. doi: 10.3816/CBC.2008.n.015 (Pubitemid 351655929)
21. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207-214 (Pubitemid 11167383)
22. Mangino P, Taft B, Djulbegovic B (1997) Criteria for grading toxicity. In: Djulbegovic B, Sullivan DM (eds) Decision making in oncology: evidence-based management, 1st edn. Churchill Livingstone, New York, pp 454-468
23. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38(3):349-358 (Pubitemid 34121962)
24. Lorusso V, Spada M, Giampaglia M, Misino A, Calabrese R, Latorre A, Monticelli G, Guida M, Sambiasi D, Colucci G (2006) Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 17(Suppl 7):15-17. doi: 10.1093/annonc/mdl942 (Pubitemid 43985171)
25. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N, Villanova G (2009) All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer 101(2):232-237. doi: 10.1038/sj.bjc.6605156
26. Delcambre C, Veyret C, Levy C, Switsers O (2005) A phase I/II study of capecitabine combined with oral vinorelbine as first or second line therapy in locally advanced or metastatic breast cancer [abstract 1081]. Breast Cancer Res Treat 94:S67
27. Campone M, Dobrovolskaya N, Tjulandin S, Chen SC, Fourie SJ, Mefti F, Konstantinova M, Lefresne F, Meheust N, Jassem J (2011) Final results of a three-arm randomised phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Abstract presented at the CTRC-AACR 2011 San Antonio Breast Cancer Symposium
28. Gampenrieder SP, Bartsch R, Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC, Steger GG (2010) Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer. Breast Care (Basel) 5(3):158-162. doi: 10.1159/000314214
29. Petrelli F, Barni S (2010) Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies. Oncol Rev 4(1):61-69
30. Rousseau F, Retornaz F, Joly F, Esterni B, Abadie-Lacourtoisie S, Fargeot P, Luporsi E, Servent V, Laguerre B, Brain E, Geneve J (2010) Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO). Crit Rev Oncol Hematol 76(1):71-78. doi: 10.1016/j.critrevonc.2009.12.003
31. Findlay M, von Minckwitz G, Wardley A (2008) Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 19(2):212-222. doi: 10.1093/annonc/mdm285 (Pubitemid 351201700)
32. Chau I, Legge S, Fumoleau P (2004) The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8(Suppl 1):S41-S53. doi: 10.1016/j.ejon.2004.06.008 (Pubitemid 39194086)
33. Faithfull S, Deery P (2004) Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 8(Suppl 1):S54-S62. doi: 10.1016/j.ejon.2004.06.009 (Pubitemid 39194087)